The first portfolio product, the Advanced Control Bioreactor System BR1000 was recently released on January 8, offering performance advantages over existing methods for biologics development. Ryan Hart is an experienced Biotechnology professional with over 14 years in the industry spending much of that time in commissioning, qualification. As part of this partnership agreement, Yokogawa will leverage ICQ Consultants’ engineering and laboratory expertise in the biopharmaceutical segment to deploy its new bioprocess technologies in the United States. Since 2007, ICQ Consultants has played an important role in the commissioning and qualification of manufacturing plants in the major life sciences hubs in the United States, including some of the world’s largest biomanufacturing facilities. These investments have driven demand for infrastructure in developing and manufacturing monoclonal antibody drugs and products that require mammalian cell bioreactor technologies. (ICQ Consultants) of Southborough have entered into a partnership agreement under which ICQ Consultants will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa’s bioreactor systems and related products in the United States.Īs a result of the COVID pandemic, the global biopharmaceutical market has been growing at an unprecedented rate, with significant investments being made in diagnostics, vaccine development, and medical devices to test and treat the coronavirus. Yokogawa Electric Corporation (Yokogawa) and Integrated Commissioning and Qualification Consultants, Corp. Yokogawa's Advanced Control Bioreactor System BR1000
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |